Stille AB (STIL) AI Stock Analysis

• Market Cap: kr2.07B
• Dividend Yield: N/A
• Average Volume (3M): 3.00K
• Price to Earnings (P/E): 39.2
• Beta (1Y): 0.54
• Revenue Growth: 26.06%
• EPS Growth: -6.03%
• Country: SE
• Employees: 162
• Sector: Healthcare
• Sector Strength: 52
• Industry: Medical - Devices
• EPS (TTM): 1.10
• Shares Outstanding: 8,985,447
• 10 Day Avg. Volume: 3,259
• 30 Day Avg. Volume: 3,003
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr259.00
• Price Target Upside: 13.60% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 75 Outperform
• Price Target: kr259.00 ▲(13.60% Upside)

Stille AB's overall stock score is driven primarily by its strong financial performance, characterized by robust revenue growth and efficient cash flow generation. Technical analysis supports a bullish outlook, although caution is advised due to potential overvaluation as indicated by the high P/E ratio. The absence of earnings call data and corporate events means these factors do not influence the score.

Stille AB Business Overview & Revenue Model

Company Description

Stille AB develops, manufactures, and sells surgical instruments in Sweden and internationally. It offers artery forceps and ligature clamps; bone cutters and rongeurs; clamps, curettes, raspatories, elevators, forceps, and micro instruments; needle holders, and wire twisting and holding forceps; and osteotomes, chisels, retractors and skin hooks, scissors, and other products, as well as c-arm tables. The company also provides ERCP/abdominal fluoroscopy, neuro/spine, pain management, urology, and vascular surgeries. In addition, it provides instrument repair, maintenance, and inspection services. Further, the company's products are used in various open surgeries. It has a collaboration agreement with GE Healthcare and distribution agreement with Synovis Micro. The company sells through OEM manufacturers of C-frames, distributors, and direct sales. The company was founded in 1841 and is headquartered in Torshälla, Sweden. Stille AB is a subsidiary of Linc AB.

How the Company Makes Money

Stille AB generates revenue through the sale of its surgical instruments and equipment to hospitals, clinics, and healthcare professionals worldwide. The company operates a direct sales model as well as partnerships with distributors to reach a broader market. Key revenue streams include the sale of standard surgical instruments, custom-designed instruments tailored to specific surgical needs, and ongoing maintenance and support services for its products. Additionally, Stille may engage in collaborations with healthcare providers for research and development purposes, which can lead to new product innovations and further enhance its market presence. The company's focus on quality and innovation allows it to maintain a competitive edge and sustain its revenue growth.

Stille AB Financial Statement Overview

Summary

Stille AB exhibits strong financial performance with robust revenue growth, efficient operations, and a solid balance sheet. The company's ability to generate cash flow is a key strength, providing flexibility for strategic initiatives. While profitability metrics are strong, there is potential for further improvement in net profit margins to align with industry leaders.

Income Statement

Stille AB demonstrates strong revenue growth with a 16.93% increase in the latest year, supported by healthy gross and net profit margins of 51.87% and 10.21%, respectively. The EBIT and EBITDA margins are robust at 14.87% and 20.87%, indicating efficient operational management. However, the net profit margin shows room for improvement compared to industry leaders.

Balance Sheet

The company's balance sheet is solid, with a low debt-to-equity ratio of 0.09, reflecting prudent financial leverage. The return on equity is moderate at 8.32%, suggesting potential for higher profitability. The equity ratio of 69.87% indicates a strong equity base, enhancing financial stability.

Cash Flow

Stille AB's cash flow performance is impressive, with a significant free cash flow growth rate of 217.02%. The operating cash flow to net income ratio of 0.54 and free cash flow to net income ratio of 0.81 highlight effective cash generation relative to earnings. This strong cash flow position supports future investments and debt servicing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	541.65M	569.95M	294.89M	246.35M	187.09M	142.63M
Gross Profit	288.43M	295.64M	132.17M	111.57M	83.46M	57.43M
EBITDA	90.20M	118.97M	56.04M	44.78M	28.89M	15.68M
Net Income	52.21M	58.21M	26.65M	27.32M	16.10M	8.27M
Balance Sheet
Total Assets	959.54M	1.00B	804.89M	342.55M	308.85M	164.90M
Cash, Cash Equivalents and Short-Term Investments	164.51M	158.49M	241.45M	36.68M	27.80M	38.12M
Total Debt	0.00	63.09M	62.94M	70.77M	81.48M	24.10M
Total Liabilities	259.77M	301.70M	172.64M	152.74M	160.75M	53.85M
Stockholders Equity	699.76M	699.40M	632.25M	189.81M	148.10M	111.05M
Cash Flow
Free Cash Flow	77.99M	59.24M	24.37M	23.89M	-11.74M	-2.89M
Operating Cash Flow	94.05M	73.53M	37.28M	31.94M	7.28M	20.56M
Investing Cash Flow	1.86M	-330.31M	-12.90M	-8.04M	-51.90M	-23.44M
Financing Cash Flow	-26.26M	171.40M	178.99M	-18.54M	33.22M	-2.75M

Stille AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 228.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:STIL, the sentiment is Positive. The current price of 228 is above the 20-day moving average (MA) of 227.20, above the 50-day MA of 226.58, and above the 200-day MA of 220.35, indicating a bullish trend. The MACD of 0.98 indicates Positive momentum. The RSI at 51.13 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:STIL.

Stille AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STIL	75 Outperform	kr2.07B	39.24		―	26.06%	-6.03%
Sector *	51 Neutral	$7.95B	-0.38	-43.43%	2.22%	22.30%	-1.83%
PXMBF	―	$194.12M	80.83	2.64%	―	―	―
SNZZF	―	$108.21M	―	-35.36%	―	―	―
24C	―	€98.12M	41.82	7.87%	―	―	―
7D2A	―	€122.32M	―	-5.40%	―	―	―
OSSD	57 Neutral	kr1.76B	―		―	36.23%	63.14%